Global Remicade Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Remicade Market was valued at $4.2 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at -4.0% CAGR, to an estimated market size of $3.4 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global Remicade market encompasses the sales of the originator biologic infliximab (Remicade) and its approved biosimilars. It includes pharmaceutical products used to treat autoimmune and inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis by inhibiting tumor necrosis factor-alpha (TNF-α). The scope excludes non-TNF-α inhibitor biologics and unrelated small-molecule therapies.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Remicade Market in the period 2025-30:
- The rapid entry of biosimilar competition is the primary driver of market value erosion as lower-cost alternatives capture significant share from the originator drug.
- The loss of patent exclusivity for Remicade has triggered aggressive price discounting and mandatory switching policies by healthcare payers.
- There is a significant clinical shift toward subcutaneous formulations, such as Zymfentra, which offer improved patient convenience over traditional intravenous infusions.
- The rising prevalence of chronic autoimmune diseases globally continues to expand the patient volume, partially offsetting the decline in total market value.
- Increasing payer pressure and government cost-containment measures are forcing a transition to biosimilars to reduce national healthcare expenditures.
- Competition from alternative therapies, including oral JAK inhibitors and newer biologics like IL-23 inhibitors, is challenging infliximab's long-term market dominance.
- The Asia-Pacific region is emerging as a key growth engine due to improving healthcare infrastructure and the expansion of domestic biosimilar manufacturing.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Rheumatoid Arthritis
- Crohn's Disease
- Ulcerative Colitis
- Other Indications